



Receipt

LAW OFFICES

ROTHWELL, FIGG, ERNST & MANBECK

A PROFESSIONAL CORPORATION

COLUMBIA SQUARE
SUITE 701 EAST TOWER
555 THIRTEENTH STREET, N.W.

WASHINGTON, D.C. 20004
TELEPHONE (202) 783-6040
FACSIMILE (202) 783-6031

www.rothwellfigg.com

G. FRANKLIN ROTHWELL
E. ANTHONY FIGG
BARBARA C. ERNST
HARRY F. MANBECK
GEORGE R. REPPER
BART G. NEWLAND
STEVEN LIEBERMAN
VINCENT M. DeLUCA
JOSEPH A. HYND
ROBERT J. JONDLE, Ph.D.†
ELIZABETH A. LEFF
STEPHEN A. SAXE, Ph.D.
MARTHA CASSIDY, Ph.D.
GREGG L. JANSEN*†
NANCY T. MORRIS*†
LISA FAHIEN ULDRICH*†
ROBERT H. CAMERON
RICHARD WYDEVEN
THOMAS E. McKIERNAN*
JASON M. SHAPIRO*
MICHAEL J. MORAN, Ph.D.*
ANNE M. STERBA
LISA N. PHILLIPS*
LEIGH M. ZANOWSKI*
C. NICHOLE GIFFORD*

* NOT ADMITTED IN D.C.
† IN NE OFFICE

OF COUNSEL
DON M. KERR*
JEFFREY L. IHLEN
GLENN E. KARTA
MARK I. BOWDITCH
MINAKSI BHATT
MIDWEST OFFICE
OMAHA, NEBRASKA

October 1, 2001

RETURN OF MISDIRECTED MAIL

Honorable Commissioner of
Patents and Trademarks
Washington, DC 20231

Re: U.S. Serial No.: 09/925,641
Filing Date: 8/10/2001

Dear Sirs:

Returned to you herewith is a Filing Receipt received in the
above matter which appears to have been sent to our firm in error.

Please charge any fee or credit any overpayment pursuant to
37 CFR 1.16 or 1.17 to Deposit Account No. 02-2135.

Respectfully submitted,

ROTHWELL, FIGG, ERNST & MANBECK, P.C.

By: Vincent M DeLuca
Vincent M. DeLuca
Registration No. 32,408



UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLAIMS	IND CLAIMS
09/925,641	08/10/2001	1635	980	P 0282794 100139/US		12	3

CONFIRMATION NO. 4423

FILING RECEIPT



OC000000006465315

ROTHWELL, FIGG, ERNST & KURZ, P.C.
555 13th Street, N.W.
Washington, DC 20004

Date Mailed: 08/23/2001

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. **If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).**

Applicant(s)

Carl John Cresswell, Macclesfield, UNITED KINGDOM;
Adam Jeston Dudley, Wilmington, DE;

Domestic Priority data as claimed by applicant

THIS APPLN CLAIMS BENEFIT OF 60/233,624 09/18/2000

Foreign Applications

UNITED KINGDOM 0020544.3 08/22/2000

If Required, Foreign Filing License Granted 08/22/2001

Projected Publication Date: To Be Determined - pending completion of Sequence Disclosures

Non-Publication Request: No

Early Publication Request: No

Title

Chemical compounds

Preliminary Class

435

RECEIVED/DOCKETING	
ROTHWELL FIGG ERNST & MANBECK	
AUG 24 2001	
REFERRED TO	_____
FILE NO.	_____
OK TO FILE	_____

Data entry by : BEGUM, SHAMIMA

Team : OIPE

Date: 08/23/2001



**LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15**

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

PLEASE NOTE the following information about the Filing Receipt:

- The articles such as "a," "an" and "the" are not included as the first words in the title of an application. They are considered to be unnecessary to the understanding of the title.
- The words "new," "improved," "improvements in" or "relating to" are not included as first words in the title of an application because a patent application, by nature, is a new idea or improvement.
- The title may be truncated if it consists of more than 500 characters (letters and spaces combined).
- The docket number allows a maximum of 25 characters.
- If your application was submitted under 37 CFR 1.10, your filing date should be the "date in" found on the Express Mail label. If there is a discrepancy, you should submit a request for a corrected Filing Receipt along with a copy of the Express Mail label showing the "date in."
- The title is recorded in sentence case.

Any corrections that may need to be done to your Filing Receipt should be directed to:

Assistant Commissioner for Patents
Office of Initial Patent Examination
Customer Service Center
Washington, DC 20231



UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
09/925,641	08/10/2001	Carl John Cresswell	P 0282794 100139/US

ROTHWELL, FIGG, ERNST & KURZ, P.C.
555 13th Street, N.W.
Washington, DC 20004

RECEIVED/DOCKETING
ROTHWELL FIGG ERNST & MANBECK

AUG 24 2001

REFERRED TO _____
FILE NO. _____
OK TO FILE _____

CONFIRMATION NO. 4423



OC000000006465316

Date Mailed: 08/23/2001

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS
CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE
DISCLOSURES**


Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- This application does not contain a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). Applicant must provide such statement. If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000).
- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

*A copy of this notice **MUST** be returned with the reply.*



A handwritten signature in black ink, appearing to be "J. H. H.", located below the circular stamp.

Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 1 - ATTORNEY/APPLICANT COPY